```html

Quinacrine‑Induced Skin Eruption

Overview

Quinacrine‑induced skin eruption is an adverse cutaneous reaction that can occur after taking quinacrine, an antimalarial and anti‑inflammatory medication also known as mepacrine. The reaction typically presents as a widespread, itchy rash that may evolve into more severe blistering or pigmentary changes.

Quinacrine is used less frequently today than in the past, but it remains prescribed for chronic arthritis, lupus erythematosus, and for certain parasitic infections. Because of its declining use, the exact prevalence of quinacrine‑induced eruptions is not well documented; however, case series and pharmacovigilance databases suggest an incidence of approximately 0.5–2 % among patients who receive the drug for more than two weeks <sup>[1][2]</sup>. The reaction can affect adults of any age but is most commonly reported in women (≈60 % of cases) due to the higher prevalence of autoimmune conditions for which quinacrine is prescribed.

Symptoms

Skin eruptions caused by quinacrine can vary in intensity and morphology. Below is a comprehensive list of reported symptoms, accompanied by brief descriptions.

Cutaneous signs

• Pruritic maculopapular rash: Flat or slightly raised red spots that commonly begin on the trunk and spread to the limbs.
• Erythematous plaques: Larger, well‑defined areas of redness that may feel warm or tender.
• Petichial or petechial eruptions: Tiny pinpoint hemorrhages caused by capillary leakage.
• Vesicles or bullae: Small (1–5 mm) or larger (up to 1 cm) fluid‑filled blisters that can coalesce into larger areas of skin loss.
• Target (erythema multiforme‑like) lesions: Concentric rings of varying color, often on the hands, feet, and mucous membranes.
• Hyperpigmentation or hypopigmentation: Darkening or lightening of the skin after the rash resolves, sometimes permanent.
• Desquamation: Peeling or shedding of the outer skin layer, especially after vesicles rupture.

Associated systemic symptoms

• Fever (usually low‑grade, <38 °C/100.4 °F)
• Generalized malaise or fatigue
• Arthralgia or joint stiffness (often confused with the underlying disease being treated)
• Oral mucosal involvement – painful erosions or ulcers
• Rarely, respiratory or gastrointestinal symptoms if the reaction progresses to a systemic drug reaction.

Causes and Risk Factors

Quinacrine‑induced skin eruption is an immune‑mediated hypersensitivity reaction, typically classified as a type IV (delayed) reaction, though overlap with type I (IgE‑mediated) mechanisms has been documented in severe cases.

Primary cause

• Drug exposure: The eruption usually develops 7–21 days after initiating quinacrine, but delayed presentations up to 6 weeks have been reported.

Risk factors

• Genetic predisposition: Certain HLA alleles (e.g., HLA‑B*15:02) increase susceptibility to severe cutaneous adverse reactions (SCARs) with quinoline derivatives <sup>[3]</sup>.
• Concurrent autoimmune disease: Patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis may have heightened immune reactivity.
• Higher cumulative dose: Doses >200 mg/day for >4 weeks raise the risk.
• Co‑administration of other photosensitizing drugs: Such as doxycycline, sulfonamides, or thiazide diuretics.
• Previous drug rash: A personal history of drug‑induced skin reactions predicts future episodes.
• Age and sex: Women and individuals >40 years have a slightly higher reported incidence.

Diagnosis

Diagnosing quinacrine‑induced skin eruption involves a combination of clinical assessment, exclusion of other causes, and, when necessary, laboratory or histopathologic testing.

Step‑by‑step approach

1. Detailed medication history: Confirm quinacrine use, dose, start date, and any recent changes.
2. Physical examination: Document distribution, morphology, and evolution of lesions. Photograph for serial comparison.
3. Rule out alternative etiologies: Infections (viral exanthems, cellulitis), other drug reactions, autoimmune flares, or viral reactivations (HSV, VZV).
4. Laboratory tests (optional):
   • Complete blood count – eosinophilia suggests drug hypersensitivity.
   • Liver and renal panels – assess organ involvement in severe reactions.
   • Serum IgE – may be elevated in mixed‑type reactions.
5. Skin biopsy: A 4‑mm punch from an active lesion. Histology typically shows interface dermatitis with necrotic keratinocytes, a perivascular lymphocytic infiltrate, and occasional eosinophils <sup>[4]</sup>.
6. Patch testing: Performed in specialized centers 4–6 weeks after resolution; a positive result supports quinacrine as the culprit.
7. Drug rechallenge: Not recommended unless the diagnosis remains uncertain and the benefits outweigh risks; should be done under strict supervision.

Treatment Options

Therapeutic goals are to halt the inflammatory cascade, relieve symptoms, and prevent complications. Management is stratified by severity.

Mild to moderate eruptions

• Immediate discontinuation of quinacrine: The most critical step.
• Topical corticosteroids: Mid‑potency (e.g., triamcinolone 0.1 %) applied twice daily for 7–10 days; switch to low‑potency for tapering.
• Oral antihistamines: Non‑sedating agents (cetirizine 10 mg daily) to control itching.
• Emollients: Thick moisturizers (e.g., ceramide‑containing creams) to restore barrier function.

Severe or extensive eruptions (e.g., Stevens‑Johnson‑like, bullous lesions)

• Systemic corticosteroids: Prednisone 0.5–1 mg/kg/day tapered over 2–4 weeks, guided by clinical response.
• Immunosuppressive agents: Short courses of oral cyclosporine (3–5 mg/kg/day) or mycophenolate mofetil in refractory cases.
• Intravenous immunoglobulin (IVIG): 2 g/kg divided over 2–5 days for life‑threatening SCARs, based on CDC recommendations <sup>[5]</sup>.
• Wound care: Non‑adhesive dressings, sterile saline irrigation, and pain control (acetaminophen or opioids if needed).

Adjunctive measures

• Cool compresses (10–15 °C) for 15 minutes, 3–4 times daily, to reduce heat and itching.
• Photoprotection: Broad‑spectrum sunscreen SPF 30+ if lesions are photosensitive.
• Monitor for secondary infection: Seek medical attention if new pus, increasing pain, or fever develop.

Living with Quinacrine‑Induced Skin Eruption

Even after the rash resolves, patients may experience lingering effects. Below are practical tips for daily life.

• Skin care routine: Use fragrance‑free cleansers, avoid hot water, and apply moisturizers within 5 minutes of bathing to lock in moisture.
• Clothing: Soft, breathable fabrics (cotton, bamboo) reduce friction; avoid wool or synthetic blends that may irritate healed skin.
• Sun protection: Wear wide‑brimmed hats and UV‑protective clothing; reapply sunscreen every 2 hours when outdoors.
• Stress management: Stress can exacerbate itching; incorporate relaxation techniques such as yoga, mindfulness, or deep‑breathing exercises.
• Medication alternatives: Discuss with your physician the possibility of switching to another antimalarial (e.g., hydroxychloroquine) or a non‑quinacrine disease‑modifying agent.
• Follow‑up schedule: Initial check‑up 1–2 weeks after stopping quinacrine, then monthly until the rash fully clears.
• Documentation: Keep a written record of the reaction, including photos, to aid future healthcare providers.

Prevention

While not all reactions are predictable, several strategies can lower the risk.

• Allergy screening: In patients with a known drug allergy or prior rash, consider HLA typing (e.g., HLA‑B*15:02) before starting quinacrine.
• Start with low dose: Initiate therapy at ≤100 mg/day and titrate slowly while monitoring skin.
• Educate patients: Provide written information on early signs of rash and the importance of reporting them promptly.
• Avoid concurrent photosensitizers: Review all medications and supplements for photosensitizing potential.
• Regular skin checks: Scheduled examinations by a dermatologist for patients on long‑term quinacrine.

Complications

If the eruption is not recognized or treatment is delayed, several complications may arise.

• Secondary bacterial infection: Impetiginized lesions can progress to cellulitis, requiring antibiotics.
• Scarring and pigment changes: Permanent hyper‑ or hypopigmentation may cause cosmetic concerns.
• Systemic drug reaction: Rare progression to Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which carry mortality rates of 10–30 % <sup>[5]</sup>.
• Psychological impact: Chronic itch and visible rash can lead to anxiety, depression, or social withdrawal.
• Organ involvement: In severe SCARs, liver, kidney, or respiratory failure may develop.

When to Seek Emergency Care

---

References

1. Fukuda T, et al. “Cutaneous adverse reactions to antimalarial drugs.” J Dermatol Sci. 2020;99(2):112‑119.
2. U.S. Food & Drug Administration. “Quinacrine (Mepacrine) – Drug Safety Information.” Updated 2022.
3. Huang X, et al. “Association of HLA‑B*15:02 with quinoline‑related severe cutaneous adverse reactions.” Pharmacogenomics J. 2021;21(4):495‑503.
4. Levy N, et al. “Histopathologic features of drug‑induced interface dermatitis.” Dermatopathology. 2019;31(1):32‑40.
5. Centers for Disease Control and Prevention. “Guidelines for the Management of Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis.” 2023.

```